- Singapore’s Mesh Bio secured funding from East Ventures.
- Mesh Bio’s Dara platform uses predictive analytics to identify patients at risk of chronic diseases.
- East Ventures sees strong potential for preventive healthcare through Mesh Bio’s digital twin engine.
Mesh Bio secures investment
Singapore-based healthtech startup Mesh Bio has secured an undisclosed investment from East Ventures, a notable investor in the tech sector.
The funding will fuel Mesh Bio’s expansion efforts in key Southeast Asian markets, including Indonesia, Malaysia, and the Philippines.
Mesh Bio, founded in 2018 by Andrew Wu and Arsen Batagov, addresses the pressing issue of non-communicable or chronic diseases, which contribute to 62% of deaths in Southeast Asia.
The company’s flagship health intelligence platform, Dara, leverages predictive analytics to identify patients at risk of chronic diseases, enabling early diagnosis and treatment.
Revolutionizing healthcare
Dara provides real-time patient data, including health history, lab tests, and medical images, empowering healthcare professionals to offer personalized counsel.
This investment comes on the heels of East Ventures’ launch of a dedicated US$30 million healthcare-focused fund.
Willson Cuaca, co-founder and managing partner at East Ventures, expressed confidence in Mesh Bio’s capabilities, stating, “Predictive analytics and preventive healthcare can provide many potential benefits for society, and we believe that Mesh Bio will lead this revolution with its digital twin engine.”
This strategic investment underscores the growing emphasis on leveraging technology to enhance predictive analytics and preventive healthcare solutions for the broader benefit of society.
